Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 6/2013

01-12-2013 | Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults

Authors: Dana Hawkinson, Daniel Hinthorn, Lara Danziger-Isakov

Published in: Current Infectious Disease Reports | Issue 6/2013

Login to get access

Abstract

Respiratory viruses cause significant morbidity and mortality in immunocompromised populations such as stem cell transplant and solid organ transplant patients. Few viruses causing respiratory tract infection have an approved therapy, and many of the viruses have no therapeutic options at all. In this article, we describe novel agents under development for treatment options against several respiratory viruses.
Literature
1.
Hayden FG. Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respir Viruses. 2013;7 Suppl 1:63–75.PubMedCrossRef
2.
De Clercq E. A cutting-edge view on the current state of antiviral drug development. Med Res Rev. Mar 11 2013.
3.
Shah DP, Ghantoji SS, Mulanovich VE, Ariza-Heredia EJ, Chemaly RF. Management of respiratory viral infections in hematopoietic cell transplant recipients. Am J Blood Res. 2012;2(4):203–18.PubMed
4.
Ison MG. Influenza, including the novel H1N1, in organ transplant patients. Curr Opin Infect Dis. 2010;23(4):365–73.PubMedCrossRef
5.
• Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an emergency IND program in the United States. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011;52(6):695–706. This study was the largest study reviewing peramivir and immunosuppressed populations.CrossRef
6.
Louie JK, Yang S, Yen C, Acosta M, Schechter R, Uyeki TM. Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09. PLoS One. 2012;7(6):e40261.PubMedCrossRef
7.
Shetty AK, Ross GA, Pranikoff T, et al. Oseltamivir-resistant 2009 H1N1 influenza pneumonia during therapy in a renal transplant recipient. Pediatr Transplant. 2012;16(5):E153–157.PubMedCrossRef
8.
Campbell AP, Jacob ST, Kuypers J, et al. Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: detection of extrapulmonary H1N1 RNA and use of intravenous peramivir. Ann Intern Med. 2010;152(9):619–20.PubMedCrossRef
9.
Renaud C, Pergam SA, Polyak C, et al. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl Infect Dis Off J Transplant Soc. 2010;12(6):513–7.CrossRef
10.
Ison MG. Influenza prevention and treatment in transplant recipients. In Process. 2013.
11.
Fraaij PL, van der Vries E, Beersma MF, et al. Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. J Infect Dis. 2011;204(5):777–82.PubMedCrossRef
12.
Ison MG. Influenza prevention and treatment in transplant Recipients and Immunocompromised Hosts. In press. 2013.
13.
Ghosh S, Adams O, Schuster FR, Borkhardt A, Meisel R. Efficient control of pandemic 2009 H1N1 virus infection with intravenous zanamivir despite the lack of immune function. Transpl Infect Dis Off J Transplant Soc. 2012;14(6):657–9.CrossRef
14.
Gaur AH, Bagga B, Barman S, et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med. 2010;362(1):88–9.PubMedCrossRef
15.
Dulek DE, Williams JV, Creech CB, et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;50(11):1493–6.CrossRef
16.
Dohna-Schwake C, Schweiger B, Felderhoff-Muser U, et al. Severe H1N1 infection in a pediatric liver transplant recipient treated with intravenous zanamivir: efficiency and complications. Transplantation. 2010;90(2):223–4.PubMedCrossRef
17.
• Kashiwagi S, Yoshida S, Yamaguchi H, et al. Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance. J Infect Chemother Off J Jpn Soc Chemother. 2013;19(2):223–32. This study showed a small number of immunsuppressed patients, but the outcome in a majority of those patients was favorable.CrossRef
18.
Ison MG. Expanding the armamentarium against respiratory viral infections: DAS181. J Infect Dis. 2012;206(12):1806–8.PubMedCrossRef
19.
Hedlund M, Larson JL, Fang F. Antiviral strategies for pandemic and seasonal influenza. Viruses. 2010;2(8):1766–81.PubMedCrossRef
20.
Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steigbigel RT. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis. 2012;206(12):1844–51.PubMedCrossRef
21.
• Triana-Baltzer GB, Gubareva LV, Klimov AI, et al. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009;4(11):e7838. Basic research evidence of DAS181 activity against neuraminidase inhibitor-resistant influenza.PubMedCrossRef
22.
Triana-Baltzer GB, Gubareva LV, Nicholls JM, et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One. 2009;4(11):e7788.PubMedCrossRef
23.
Chan RW, Chan MC, Wong AC, et al. DAS181 inhibits H5N1 influenza virus infection of human lung tissues. Antimicrob Agents Chemother. 2009;53(9):3935–41.PubMedCrossRef
24.
Belser JA, Lu X, Szretter KJ, et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis. 2007;196(10):1493–9.PubMedCrossRef
25.
Morello J, Rodriguez-Novoa S, Jimenez-Nacher I, Soriano V. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother. 2008;62(6):1174–80.PubMedCrossRef
26.
Pelaez A, Lyon GM, Force SD, et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2009;28(1):67–71.CrossRef
27.
Li L, Avery R, Budev M, Mossad S, Danziger-Isakov L. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2012;31(8):839–44.CrossRef
28.
Feltes TF, Sondheimer HM, Tulloh RM, et al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res. 2011;70(2):186–91.PubMedCrossRef
29.
•• Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis. 2001;184(3):350–4. Significant early study showing efficacy in prevention of upper-to-lower respiratory tract disease in transplant populations.PubMedCrossRef
30.
Kassis C, Champlin RE, Hachem RY, et al. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2010;16(9):1265–71.CrossRef
31.
Liu V, Dhillon GS, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transplant Infect Dis Off J Transplant Soc. 2010;12(1):38–44.CrossRef
32.
• Zamora MR, Budev M, Rolfe M, et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2011;183(4):531–8. Significant paper showing efficacy of novel molecular agents as therapeutic options.PubMedCrossRef
33.
• Simon A, Karsten V, Cehelsky J, Bettencourt B, Gollob J, Meyers R, Nochur S, Vaishnaw A, Glanville A, Zamora M, DeVincenzo J, Arcasoy S, Musk M, Sommerwerk U, Gottlieb J. Results of a phase 2b multi-center trial of ALN-RSV01 in Respiratory Syncytial Virus (RSV)-infected lung transplant patients. Paper presented at: Europen Respiratory Society Annual Congress2012. Significant paper showing efficacy of novel molecular agents as therapeutic options.
34.
Schepens B, Ibanez LI, De Baets S, et al. Nanobodies(R) specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J Infect Dis. 2011;204(11):1692–701.PubMedCrossRef
35.
Weigt SS, Gregson AL, Deng JC, Lynch 3rd JP, Belperio JA. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med. 2011;32(4):471–93.PubMedCrossRef
36.
• Drozd DR, Limaye AP, Moss RB, et al. DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient. Transplant Infect Dis Off J Transplant Soc. 2013;15(1):E28–32. Impotant case report using DAS181 to treat severe parainfluenza in lung transplant recipient.CrossRef
37.
• Chen YB, Driscoll JP, McAfee SL, et al. Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011;53(7):e77–80. Impotant case report using DAS181 to treat severe parainfluenza in stem cell transplant recipient.CrossRef
38.
• Guzman-Suarez BB, Buckley MW, Gilmore ET, et al. Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients. Transplant Infect Dis Off J Transplant Soc. 2012;14(4):427–33. Impotant case report using DAS181 to treat severe parainfluenza in stem cell transplant patients.CrossRef
39.
Lau SK, Yip CC, Tsoi HW, et al. Clinical features and complete genome characterization of a distinct human rhinovirus (HRV) genetic cluster, probably representing a previously undetected HRV species, HRV-C, associated with acute respiratory illness in children. J Clin Microbiol. 2007;45(11):3655–64.PubMedCrossRef
40.
Gutman JA, Peck AJ, Kuypers J, Boeckh M. Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplantation patients: a report of two cases. Bone Marrow Transplant. 2007;40(8):809–11.PubMedCrossRef
41.
Parody R, Rabella N, Martino R, et al. Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies. Am J Hematol. 2007;82(9):807–11.PubMedCrossRef
42.
Milano F, Campbell AP, Guthrie KA, et al. Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. Blood. 2010;115(10):2088–94.PubMedCrossRef
43.
Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;56(2):258–66.CrossRef
44.
Matz J. Vapendavir for the treatment of naturally acquired rhinovirus infection in asthmatic adults: effect on asthma control in a phase 2 clinical trial. Paper presented at: American Thoracic Society International Conference 2013.
45.
Lynch 3rd JP, Fishbein M, Echavarria M. Adenovirus. Semin Respir Crit Care Med. 2011;32(4):494–511.PubMedCrossRef
46.
Robinson CM, Singh G, Lee JY, et al. Molecular evolution of human adenoviruses. Sci Rep. 2013;3:1812.PubMedCrossRef
47.
Mayeur N, Srairi M, Tetu L, Guilbeau Frugier C, Fourcade O, Dahan M. Lethal hemorrhagic alveolitis after adenovirus pneumonia in a lung transplant recipient. Heart Lung J Crit Care. 2012;41(4):401–3.CrossRef
48.
Yilmaz M, Chemaly RF, Han XY, et al. Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant. Mar 18 2013.
49.
Gu L, Liu Z, Li X, et al. Severe community-acquired pneumonia caused by adenovirus type 11 in immunocompetent adults in Beijing. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2012;54(4):295–301.CrossRef
50.
Matthes-Martin S, Feuchtinger T, Shaw PJ, et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transplant Infect Dis Off J Transplant Soc. 2012;14(6):555–63.CrossRef
51.
•• Grimely M, Papnicolaou, G, Prasad, V. CMX001 is a potential treatment for adenovirus infection: preliminary antiviral activity results from an open-label, expanded access study of CMX001 for the treatment of serious or lifethreatening diseases caused by doublestranded DNA Viruses. Paper presented at: European Group for Blood and Marrow Transplantation Annual Meeting2013. Important data regarding effectiveness of CMX001 as salvage therapy in patients with severe disease.
52.
•• Florescu DF, Pergam SA, Neely MN, et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2012;18:731–8. Showed improved outcomes as well as low side effects when using CMX001 for severe aqdenovirus infections.CrossRef
53.
Geller C, Varbanov M, Duval RE. Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies. Viruses. 2012;4(11):3044–68.PubMedCrossRef
54.
Adedeji AO, Severson W, Jonsson C, Singh K, Weiss SR, Sarafianos SG. Novel inhibitors of SARS-CoV entry acting by three distinct mechanisms. J Virol. May 15 2013.
55.
Elshabrawy HA, Coughlin MM, Baker SC, Prabhakar BS. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS One. 2012;7(11):e50366.PubMedCrossRef
56.
Schneider M, Ackermann K, Stuart M, et al. Severe acute respiratory syndrome coronavirus replication is severely impaired by MG132 due to proteasome-independent inhibition of M-calpain. J Virol. 2012;86(18):10112–22.PubMedCrossRef
57.
Li Q, Zhao Z, Zhou D, et al. Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. Peptides. 2011;32(7):1518–25.PubMedCrossRef
Metadata
Title
Novel Antiviral Agents for Respiratory Viral Infection in Immunocompromised Adults
Authors
Dana Hawkinson
Daniel Hinthorn
Lara Danziger-Isakov
Publication date
01-12-2013
Publisher
Springer US
Published in
Current Infectious Disease Reports / Issue 6/2013
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-013-0370-0

Other articles of this Issue 6/2013

Current Infectious Disease Reports 6/2013 Go to the issue

Healthcare Associated Infections (G Bearman and M Stevens, Section Editors)

Challenges in Measuring Antibiotic Consumption

Central Nervous System (J Lyons, Section Editor)

Neurological Complications in Controlled HIV Infection

Invited Commentary

Does the Nose Know? An Update on MRSA Decolonization Strategies

CENTRAL NERVOUS SYSTEM (J LYONS, SECTION EDITOR)

Central Nervous System Tuberculosis: Challenges and Advances in Diagnosis and Treatment

Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Organ Transplantation in HIV Patients: Current Status and New Directions

Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Infectious Complications of Immune Modulatory Agents
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits